Raymon Heather,Narla Rama K.,Mortensen Deborah,Hege Kristen Mae,Fultz Kimberly Elizabeth,Tsuji Toshiya
申请号：
NZ71788713
公开号：
NZ717887A
申请日:
2013.10.17
申请国别(地区):
NZ
年份:
2017
代理人:
摘要：
Provided are methods for treating prostate cancer using TOR kinase (mTOR) inhibitors. Further provided are methods of determining the response of prostate cancers to TOR kinase inhibitors by measuring the phosphorylation of S6RP, 4E-BP1, AKT or DNA-PK. In an embodiment the TOR kinase inhibitor is a compound of formula (IV), where the variables are as defined in the specification, such as 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one .
